VRCA Verrica Pharmaceuticals Inc.

NASDAQ
$2.88

Verrica Pharmaceuticals Inc. (VRCA) is expected to report earnings on February 11, 2027, after the market close. The consensus earnings estimate is a loss of $0.72 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -23.2% since its last earnings release on November 12, 2026.

Verrica Pharmaceuticals Missed Consensus Estimates
Thursday, November 12, 2026 · 4:16 PM ET
Earnings Date
4th Quarter, Dec 2026
Feb 11
Thursday · 4:05 PM ET
Earnings Whisper
-
vs ($0.72)
Rev est $7.08M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $3.13

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Verrica Pharmaceuticals Inc.

Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. Verrica’s late-stage product candidate, VP-102, is in development to treat molluscum, common warts and external genital warts, three of the largest unmet needs in medical dermatology. Verrica is also developing VP-103, its second cantharidin-based product candidate, for the treatment of plantar warts. The Company has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatologic oncology conditions.

Sector

Healthcare

Industry

Drug Manufacturers/Other

Charts powered in part by Lightweight Charts™ by TradingView.